Operating Expenses

Deferred Rent Expense

Year-over-year, this metric grew by 65.9%, from -$191.60M to -$65.30M.

Analysis

StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026

How to read this metric

An increase suggests that cash payments are currently lower than the straight-line expense, while a decrease indicates the opposite.

Detailed definition

This metric captures the accounting adjustment required to recognize lease costs on a straight-line basis over the lease...

Peer comparison

Common in companies with significant real estate footprints; standard accounting practice under ASC 842.

Metric ID: tmusz_deferred_rent_expense

Historical Data

17 periods
 Q2 '21Q4 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value-$237.90M-$41.90M-$12.30M-$229.40M-$182.30M-$134.13M-$134.13M-$134.13M-$134.13M-$158.30M-$118.80M-$123.30M-$191.60M-$113.80M-$235.90M$0.00-$65.30M
QoQ Change+82.4%+70.6%<-999%+20.5%+26.4%+0.0%+0.0%+0.0%-18.0%+25.0%-3.8%-55.4%+40.6%-107.3%+100.0%
YoY Change+3.6%-990.4%+41.5%+26.4%-18.0%+11.4%+8.1%-21.0%+4.2%-91.3%+65.9%
Range-$237.90M$0.00
CAGR-27.6%
Avg YoY Growth-87.2%
Median YoY Growth+4.2%
Current Streak2 quarters growth

Frequently Asked Questions

What is Vertex Pharmaceuticals's deferred rent expense?
Vertex Pharmaceuticals (VRTX) reported deferred rent expense of -$65.30M in Q1 2026.
How has Vertex Pharmaceuticals's deferred rent expense changed year-over-year?
Vertex Pharmaceuticals's deferred rent expense increased by 65.9% year-over-year, from -$191.60M to -$65.30M.
What does deferred rent expense mean?
The difference between actual cash rent paid and the average rent expense recognized over the life of a lease.